Alexandra Gerlach, Editor

Secondhand exposure to e-cigarette smoke may increase risk of pediatric atopic dermatitis in children.

The FDA approved blinatumomab for treatment of patients with CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia.

Zanubrutinib shows potential in treating patients with treatment-naïve high-risk chronic lymphocytic leukemia and/or small lymphocytic lymphoma with del(17p) and/or TP53 mutation.

Trametinib may become an alternative treatment to hematopoietic stem cell transplantation in patients with relapsed or refractory juvenile myelomonocytic leukemia (JMML).

Amplification of chromosome 1q is associated with poorer treatment outcomes for patients with relapsed/refractory and newly diagnosed multiple myeloma.

Reducing sodium intake is associated with decreased risk of atopic dermatitis (AD) and flares.

Eating a poor diet might lead to structural brain changes that cause the development of common mental disorders (CMD).

Continuous glucose monitoring systems offer timely biofeedback for patients with type 2 diabetes.

Research has found that increased consumption of sugar alcohols, like xylitol, may increase risk of cardiovascular events.

Osimertinib demonstrates improved progression-free survival for stage 3 epidermal growth factor receptor-mutated (EGFRm) lung cancer.

Study reveals vigorous physical activity correlates with lower rates of cognitive impairment in hypertensive patients.

Over the course of 15 years, epigenetic and transcriptional analysis of postmortem brain samples have revealed underlying molecular differences.

Data show women with poor cardiovascular health may have an increased risk of early signs of cognitive decline in midlife.

Daratumumab in combination with standard treatment regimens shows benefit in multiple myeloma.

The priority review of inavolisib is for treatment of patients with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation.

Quadruple therapies including immunotherapy agents show promise in treating patients with multiple myeloma.

Gender disparities among oncology health care professionals have significant consequences for both the physicians and the patients they treat.

Isatuximab is used in combination with bortezomib, lenalidomide, and dexamethanose.

UC Davis Health researchers uncover substantial treatment disparities and inequal access to autologous hematopoietic cell transplantation therapy among multiple myeloma patients.

Speakers at the 2024 Society of Pain and Palliative Care Virtual Conference discussed advanced treatment opportunities for patients with substance use disorder (SUD) and cancer-related pain.

Continued disparities of gender representation in cardiovascular research reveal oversights that impact adequate diagnosis and treatment of cardiovascular disease in women.

A lipoprotein (a) (Lp[a]) assay has been granted breakthrough device designation to expand identification of patients with elevated Lp(a) and genetic predispositions to cardiovascular disease.

Inavolisib was submitted to the FDA for review as a first-line treatment for advanced HR-positive, HER2-negative PIK3CA-mutated breast cancer.

Researchers from the University of Leipzig Medical Center identify multiple biomarkers associated with the success of CAR T cell therapy in relapsed multiple myeloma.

New research reveals the potential of community pharmacists in minor ailment treatment, allowing for diversified patient care during growing health care professional shortages.

Researchers from the University of Manchester have developed a technique using rotaxane actuators in force-controlled release systems, enabling precise and efficient release of multiple molecules simultaneously.